Octarine Bio adds €5 million to Series A
The extension brought the Danish biotech company’s cumulative Series A financing to €12.8 million.
Octarine Bio announced an additional €5 million in financing on January 22, 2026, completing a Series A package totalling €12.8 million, including earlier pre-Series A funding. The new capital will support industrial validation and the commercial rollout of its PurePalette pigments.
Participants included The Footprint Firm, Edaphon, Unconventional Ventures, dsm-firmenich Ventures and Óskare Capital. Business angels included former Novozymes executives Per Falholt and Steen Riisgaard.
The Copenhagen company uses precision fermentation and enzyme technology to produce bio-based colours. It plans to scale its first three flagship colours, execute existing commercial partnerships and expand development for applications beyond textiles, including food and cosmetics.
Use of funds
Industrial-scale validation and commercial rollout of PurePalette bio-based pigments